HLUNBC:AQUISEUH. Lundbeck A/S Class B Analysis

H. Lundbeck A/S is trading at DKK 37.59, precisely at its identified support level, and sits below its 20‑day (39.12), 50‑day (40.79) and 200‑day (40.64) simple moving averages, indicating a short‑term bearish bias. However, the RSI of 17 signals a deep oversold condition, while volume is on an upward trend, suggesting a potential near‑term bounce. The MACD histogram remains negative, reinforcing the current downside momentum but not precluding a reversal at the support zone.
Fundamentally, the stock appears markedly undervalued: a trailing P/E of 11.7 is less than half the industry average of 26.2, and the DCF‑derived fair value of roughly DKK 74 is double the market price. The company delivers a solid 3.06% dividend yield with a modest 30% payout ratio, strong cash generation (operating cash flow > DKK 5.4 bn), and a healthy gross margin of 82.7%, though leverage is moderate (debt‑to‑equity ~47%). Volatility is high (≈ 47% 30‑day) yet beta is ultra‑low (~0.08), indicating price swings are largely company‑specific rather than market‑driven.
Given the valuation gap, sustainable dividend, and a robust pipeline of neuro‑psychiatric drugs, the medium‑ and long‑term outlook is positive. Short‑term investors may hold to gauge a technical rebound, while longer‑term holders can consider adding positions to capture the upside potential toward the DCF target.